These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 23383655)

  • 1. Virological response and safety of 24-week telaprevir alone in Japanese patients infected with hepatitis C virus subtype 1b.
    Toyota J; Ozeki I; Karino Y; Asahina Y; Izumi N; Takahashi S; Kawakami Y; Chayama K; Kamiya N; Aoki K; Yamada I; Suzuki Y; Suzuki F; Kumada H
    J Viral Hepat; 2013 Mar; 20(3):167-73. PubMed ID: 23383655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, pharmacokinetics and resistant variants of telaprevir alone for 12 weeks in hepatitis C virus genotype 1b infection.
    Yamada I; Suzuki F; Kamiya N; Aoki K; Sakurai Y; Kano M; Matsui H; Kumada H
    J Viral Hepat; 2012 Feb; 19(2):e112-9. PubMed ID: 22239508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C.
    Hara T; Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Kumada H
    J Med Virol; 2013 Oct; 85(10):1746-53. PubMed ID: 23861088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.
    Furusyo N; Ogawa E; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
    J Hepatol; 2013 Aug; 59(2):205-12. PubMed ID: 23542346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C.
    Buti M; Agarwal K; Horsmans Y; Sievert W; Janczewska E; Zeuzem S; Nyberg L; Brown RS; Hézode C; Rizzetto M; Paraná R; De Meyer S; De Masi R; Luo D; Bertelsen K; Witek J
    Gastroenterology; 2014 Mar; 146(3):744-753.e3. PubMed ID: 24316262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients.
    Ozeki I; Akaike J; Karino Y; Arakawa T; Kuwata Y; Ohmura T; Sato T; Kamiya N; Yamada I; Chayama K; Kumada H; Toyota J
    J Gastroenterol; 2011 Jul; 46(7):929-37. PubMed ID: 21556829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients.
    Kieffer TL; Sarrazin C; Miller JS; Welker MW; Forestier N; Reesink HW; Kwong AD; Zeuzem S
    Hepatology; 2007 Sep; 46(3):631-9. PubMed ID: 17680654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.
    McHutchison JG; Everson GT; Gordon SC; Jacobson IM; Sulkowski M; Kauffman R; McNair L; Alam J; Muir AJ;
    N Engl J Med; 2009 Apr; 360(18):1827-38. PubMed ID: 19403902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials.
    Kieffer TL; De Meyer S; Bartels DJ; Sullivan JC; Zhang EZ; Tigges A; Dierynck I; Spanks J; Dorrian J; Jiang M; Adiwijaya B; Ghys A; Beumont M; Kauffman RS; Adda N; Jacobson IM; Sherman KE; Zeuzem S; Kwong AD; Picchio G
    PLoS One; 2012; 7(4):e34372. PubMed ID: 22511937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telaprevir-based therapy in patients coinfected with chronic hepatitis C virus infection and HIV: INSIGHT study.
    Montes ML; Nelson M; Girard PM; Sasadeusz J; Horban A; Grinsztejn B; Zakharova N; Rivero A; Durant J; Ortega-Gonzalez E; Lathouwers E; Janssen K; Ouwerkerk-Mahadevan S; Witek J; González-García J
    J Antimicrob Chemother; 2016 Jan; 71(1):244-50. PubMed ID: 26483516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial.
    Reddy KR; Zeuzem S; Zoulim F; Weiland O; Horban A; Stanciu C; Villamil FG; Andreone P; George J; Dammers E; Fu M; Kurland D; Lenz O; Ouwerkerk-Mahadevan S; Verbinnen T; Scott J; Jessner W
    Lancet Infect Dis; 2015 Jan; 15(1):27-35. PubMed ID: 25482330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1.
    Akuta N; Suzuki F; Seko Y; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2012 Jul; 84(7):1097-105. PubMed ID: 22585728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for non-cirrhotic patients with chronic hepatitis C virus genotype 1b infection.
    Ogawa E; Furusyo N; Kajiwara E; Nomura H; Kawano A; Takahashi K; Dohmen K; Satoh T; Azuma K; Nakamuta M; Koyanagi T; Kotoh K; Shimoda S; Hayashi J
    J Gastroenterol Hepatol; 2015 Dec; 30(12):1759-67. PubMed ID: 26095167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telaprevir for previously untreated chronic hepatitis C virus infection.
    Jacobson IM; McHutchison JG; Dusheiko G; Di Bisceglie AM; Reddy KR; Bzowej NH; Marcellin P; Muir AJ; Ferenci P; Flisiak R; George J; Rizzetto M; Shouval D; Sola R; Terg RA; Yoshida EM; Adda N; Bengtsson L; Sankoh AJ; Kieffer TL; George S; Kauffman RS; Zeuzem S;
    N Engl J Med; 2011 Jun; 364(25):2405-16. PubMed ID: 21696307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
    Hézode C; Forestier N; Dusheiko G; Ferenci P; Pol S; Goeser T; Bronowicki JP; Bourlière M; Gharakhanian S; Bengtsson L; McNair L; George S; Kieffer T; Kwong A; Kauffman RS; Alam J; Pawlotsky JM; Zeuzem S;
    N Engl J Med; 2009 Apr; 360(18):1839-50. PubMed ID: 19403903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telaprevir activity in treatment-naive patients infected hepatitis C virus genotype 4: a randomized trial.
    Benhamou Y; Moussalli J; Ratziu V; Lebray P; De Backer K; De Meyer S; Ghys A; Luo D; Picchio GR; Beumont M
    J Infect Dis; 2013 Sep; 208(6):1000-7. PubMed ID: 23801602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan.
    Kumada H; Toyota J; Okanoue T; Chayama K; Tsubouchi H; Hayashi N
    J Hepatol; 2012 Jan; 56(1):78-84. PubMed ID: 21827730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.
    Aherfi S; Solas C; Motte A; Moreau J; Borentain P; Mokhtari S; Botta-Fridlund D; Dhiver C; Portal I; Ruiz JM; Ravaux I; Bregigeon S; Poizot-Martin I; Stein A; Gérolami R; Brouqui P; Tamalet C; Colson P
    J Med Virol; 2014 Nov; 86(11):1868-76. PubMed ID: 25052594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
    Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of telaprevir (TVR) triple therapy in a 'real-life' cohort of 102 patients with HCV genotype 1: interim analysis after 24 weeks of treatment.
    Werner CR; Franz C; Egetemeyr DP; Janke-Maier P; Malek NP; Lauer UM; Berg CP
    J Viral Hepat; 2014 May; 21(5):333-40. PubMed ID: 24716636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.